Reaction

Dermatomyositis reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 2,505 reports · 60 co-occurring drugs

As of the last recalculation, Dermatomyositis appears in 2,505 FAERS reports alongside 60 co-occurring drug terms. The strongest observed disproportionality signal is HUMAN IMMUNOGLOBULIN G (PRR 24.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Human Immunoglobulin G	60	24.7	24.8
Tofacitinib Citrate	27	17.3	17.3
Hydroxychloroquine	126	14.7	14.7
Diphenhydramine Hydrochloride Capsule, Liquid Filled	35	13.8	13.8
Hydroxyurea	31	12.3	12.3
Azathioprine	111	10.9	10.9
Mycophenolate Mofetil	165	10.7	10.7
Mycophenolate Mofetil Hydrochloride	165	10.7	10.7
Adalimumab-Fkjp	57	10.4	10.5
Adalimumab-Aaty	58	10.4	10.4
Nivolumab	103	9.2	9.2
Hydroxychloroquine Sulfate	97	9.2	9.2
Adalimumab-Adaz	57	9.2	9.2
Methylprednisolone	140	8.9	8.9
Docetaxel Anhydrous	70	8.8	8.9
Docetaxel	70	8.8	8.9
Atezolizumab	36	7.8	7.8
Trastuzumab	63	7.8	7.8
Prochlorperazine Maleate	8	7.2	7.2
Rituximab	171	7.1	7.1
Ipilimumab	34	6.6	6.6
Methotrexate	297	6.5	6.5
Pertuzumab	21	6.5	6.5
Methotrexate Sodium	333	6.4	6.4
Mycophenolic Acid	24	6.3	6.3
Baricitinib	7	6.0	6.1
Mycophenilic Acid	15	6.0	6.0
Anastrozole Tablets	15	5.8	5.8
Tacrolimus Ointment 0.1%	82	5.6	5.6
Tacrolimus Extended-Release Capsules	82	5.6	5.6
Tacrolimus	102	5.6	5.6
Carboplatin	80	5.4	5.4
Triamcinolone Acetonide Ointment Usp, 0.05%	15	5.3	5.4
Atorvastatin Calcium, Film Coated	44	5.3	5.3
Eplerenone	8	5.2	5.2
Sulfasalazine	48	5.2	5.2
Pembrolizumab	61	4.9	4.9
Nintedanib	18	4.8	4.8
Cyclophosphamide Injection, Solution	95	4.6	4.6
Cyclophosphamide	95	4.6	4.6
Cyclophosphamide For Injection	95	4.6	4.6
Paclitaxel (Aibumin-Bound)	44	4.5	4.5
Tofacitinib	94	4.4	4.4
Triamcinolone Acetonide	16	4.3	4.3
Paclitaxel	50	4.3	4.3
Capecitabine	46	4.2	4.2
Oseltamivir	4	4.2	4.2
Asfotase Alfa	5	4.2	4.2
Olaparib	10	4.0	4.0
Etoposide	33	3.8	3.8
Fluorouracil	34	3.7	3.7
Durvalumab	9	3.7	3.7
Fluorouracil Cream, 0.5%	33	3.6	3.6
Pemetrexed	9	3.5	3.5
Fremanezumab-Vfrm	4	2.9	2.9
Crisaborole	3	2.6	2.6
Remdesivir	4	2.5	2.5
Abemaciclib	5	2.1	2.1
Abiraterone Acetate	10	2.0	2.0
Lifitegrast	3	1.5	1.5

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.